Efficacy and Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis: A Meta-Analysis and Cost-Efficacy Analysis Using the Intention-to-Treat Principle

Table 4

Base case incremental analysis.

	6-month costs	Incremental efficacy of PASI 75 response	ICER (costs per additional PASI 75 responder)
Etanercept	$17,954	55%	Dominated
Adalimumab	$13,429	63%	$21,315^a
Ustekinumab 45 mg	$16,787	67%	$83,950^b
Infliximab	$19,725	71%	$68,175^c
Ustekinumab 90 mg	$33,574	72%	$1,384,900^d
		Incremental efficacy of PGA 0/1 response	ICER (costs per additional PGA 0/1 responder)
Adalimumab	$13,429	56%	$23,980^a
Ustekinumab 45 mg	$16,787	58%	$167,900^b
Etanercept	$17,954	58%	Dominated
Ustekinumab 90 mg	$33,574	62%	$3,358,150^c
Infliximab	$19,725	69%	$26,709^c

aCompared to placebo.
^bCompared to adalimumab.
^cCompared to ustekinumab 45 mg.
^dCompared to infliximab.